| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2025―Aug―13 |
Safety, Tolerability, and Pharmacokinetics of the Long-Acting SARS-CoV-2-Neutralizing Monoclonal Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) in Healthy Chinese Adults |
Nanyang Li, Jing Zhang, Wenhong Zhang, Zhongyuan Xu, Xiangcao Yao, Anqi He, Shuyuan Liu, Xiaoyun Ge, Jinxi Liu, Yunfei Li, Cecil Chi-Keung Chen, Huixia Zhang |
| 2 |
[GO] |
2022―Oct―26 |
Safety, Tolerability, and Pharmacokinetics of Intravenous Doses of PF-07304814, a Phosphate Prodrug Protease Inhibitor for the Treatment of SARS-CoV-2, in Healthy Adult Participants |
Tong Zhu, Sylvester Pawlak, Sima S. Toussi, Frances Hackman, Kimberly Thompson, Wei Song, Joanne Salageanu, Erica Winter, Haihong Shi, Jennifer Winton, Michael Binks |
|
